HSA eCTD Therapeutic Product Registration 2026

The Health Sciences Authority (HSA) officially accepts electronic Common Technical Document (eCTD) packages for therapeutic-product regulatory dossier submissions with effect from 1 April 2026. The change concerns how companies submit registration dossiers; it does not itself approve a therapeutic product or replace HSA’s substantive regulatory assessment (HSA, 31 Mar 2026).

Standard and submission route

Companies may submit actual eCTD dossiers through HSA’s eCTD portal using SG-HSA eCTD version 1.1, which HSA describes as the official standard for eCTD submissions. HSA also provides technical files for defined lists, a document matrix, a submission-type matrix and an updated Singapore-specific regional stylesheet for preparation and validation (HSA, 31 Mar 2026).

The standard is therefore more than a choice to send documents electronically. An applicant must prepare the package in the Singapore-specific structure and use the current technical and validation resources, including the defined lists and matrices that identify permitted values and document or submission types. The portal is the submission route for an actual dossier; it is not merely a test-upload site or a general HSA contact form. Applicants should check the current package and portal instructions before submission because HSA’s eCTD implementation is phased and the online resources are the controlling technical references (HSA, eCTD submissions).

Implementation support and boundary

HSA published a training presentation, Q&A document and portal user manual to support users navigating the new submission system. The announcement is an electronic-format and portal-acceptance update; applicants must still follow HSA’s wider therapeutic-product registration guidance and should not interpret eCTD acceptance as a guarantee of registration or as a new product-eligibility category (HSA, 31 Mar 2026).

The support materials address different implementation needs: training and presentation materials explain the workflow, the Q&A addresses recurring industry questions, and the user manual supports portal operation. None of these resources replaces the substantive registration guidance, application checklists or HSA directions for a particular product and submission type. A technically valid upload may still require correction, further information or substantive regulatory review. The safest interpretation is that eCTD changes the dossier-delivery mechanism and preparation tools, while the applicant’s legal, scientific and administrative responsibilities continue under the therapeutic-product registration framework (HSA, eCTD submissions).

Voluntary rollout and initial scope

HSA describes the eCTD rollout as voluntary and says companies may continue using current non-eCTD submission modes, while encouraging industry to transition. The initial launch is open to new drug applications, generic drug applications and their corresponding Drug Master File submissions. HSA says it will give advance notice before later phases of the rollout; therefore, the 1 April 2026 acceptance date should not be read as a universal requirement that every therapeutic-product submission already use eCTD. (HSA, eCTD submissions, updated 26 May 2026, accessed 8 September 2026.)

The initial scope is consequently defined by both format status and application type. HSA says the launch is open to new drug applications, generic drug applications and corresponding Drug Master File submissions, while the wider rollout is to be phased. A company should not infer from the availability of the portal that every variation, product class or regulatory transaction is already included in the first phase. Conversely, voluntary use does not mean an applicant can ignore HSA’s preferred technical standard when choosing eCTD. The current page’s wording—accepted, voluntary, initially open to named submission types, with advance notice before later phases—should be preserved when describing the 2026 position (HSA, eCTD submissions).

Portal, validation and lifecycle-management role

The eCTD portal is intended to support paperless transfer of structured regulatory information, with online technical files, defined lists, document and submission-type matrices, and validation resources for the SG-HSA package. HSA explains that standardised eCTD submissions can reduce reliance on physical storage media and support product lifecycle management, including reuse of common dossier content. This is a submission and information-management capability: HSA’s substantive review, applicant responsibilities and product-registration decisions still apply separately. (HSA, eCTD submissions, updated 26 May 2026, accessed 8 September 2026.)

Lifecycle management is relevant because a therapeutic-product dossier can receive later sequences, updates or related regulatory communications. Standardised electronic structure can make those changes easier to organise and validate, but it does not make a later sequence automatically acceptable or convert a submission into a registration decision. The portal and technical package help HSA and industry transfer and manage information; they do not determine clinical, quality or safety conclusions. Product status must therefore be established from HSA’s substantive regulatory outcome, not from the fact that an applicant has uploaded an eCTD package (HSA, eCTD submissions).

Related submission-quality control from 1 June 2026

HSA’s 31 March 2026 regulatory update also introduced a separate submission-quality requirement: from 1 June 2026, applicants must provide an official letter declaring that there are no known quality defects requiring amendment or updates to the submitted Chemistry, Manufacturing and Controls (CMC) dossier (HSA, regulatory updates). This control is related to the wider therapeutic-product submission process but is not an eCTD-format requirement. It is intended to reduce the inadvertent submission of superseded technical data and improve regulatory efficiency. Applicants should therefore distinguish three questions: whether the dossier is submitted in eCTD or another accepted mode; whether the package meets SG-HSA technical validation requirements; and whether the substantive CMC information is current and accompanied by any required declaration. eCTD acceptance does not cure a defective or outdated dossier, and the quality-defect declaration does not make an application eligible or guarantee registration.